Literature DB >> 2915374

Frequency of 13q abnormalities among 203 patients with retinoblastoma.

G R Bunin1, B S Emanuel, A T Meadows, J D Buckley, W G Woods, G D Hammond.   

Abstract

We studied peripheral blood lymphocyte karyotypes of 203 patients with retinoblastoma. Twelve (5.9%) had a constitutional chromosomal abnormality involving 13q, of whom six had unilateral and six had bilateral disease. Two patients had mosaic deletions, eight had nonmosaic deletions, one had a de novo translocation, and one had a 13q14 deletion and a de novo direct insertion (10;6). Of the total, 4.9% of unilateral and 7.5% of bilateral patients had 13q abnormalities. None of 19 familial retinoblastoma patients had a visible cytogenetic abnormality. The unilateral patients with 13q abnormalities represent prezygotically determined (potentially heritable) cases which would have been classified as postzygotic (sporadic) without cytogenetic analysis. The observed 1% frequency of mosaic deletions is lower than that previously reported.

Entities:  

Mesh:

Year:  1989        PMID: 2915374     DOI: 10.1093/jnci/81.5.370

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

1.  Pars plana ciliary epithelial proliferation in 13q deletion syndrome.

Authors:  Y Usui; N A Rao
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

2.  Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma.

Authors:  D R Lohmann; M Gerick; B Brandt; U Oelschläger; B Lorenz; E Passarge; B Horsthemke
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

3.  Developmental and adaptive functioning in children with retinoblastoma: a longitudinal investigation.

Authors:  Victoria W Willard; Ibrahim Qaddoumi; Si Chen; Hui Zhang; Rachel Brennan; Carlos Rodriguez-Galindo; Matthew W Wilson; Sean Phipps
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

4.  Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities.

Authors:  Rachel C Brennan; Ibrahim Qaddoumi; Catherine A Billups; Tracy Kaluzny; Wayne L Furman; Matthew W Wilson
Journal:  Pediatr Blood Cancer       Date:  2016-07-13       Impact factor: 3.167

Review 5.  Mendelian cytogenetics. Chromosome rearrangements associated with mendelian disorders.

Authors:  N Tommerup
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

6.  Radiographic findings in 13q-syndrome.

Authors:  S C Kaste; C B Pratt
Journal:  Pediatr Radiol       Date:  1993

7.  Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions.

Authors:  Diana Mitter; Reinhard Ullmann; Artur Muradyan; Ludger Klein-Hitpass; Deniz Kanber; Katrin Ounap; Marc Kaulisch; Dietmar Lohmann
Journal:  Eur J Hum Genet       Date:  2011-04-20       Impact factor: 4.246

8.  A longitudinal investigation of parenting stress in caregivers of children with retinoblastoma.

Authors:  Victoria W Willard; Ibrahim Qaddoumi; Hui Zhang; Lu Huang; Kathryn M Russell; Rachel Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Sean Phipps
Journal:  Pediatr Blood Cancer       Date:  2016-11-03       Impact factor: 3.167

9.  Fine mapping of whole RB1 gene deletions in retinoblastoma patients confirms PCDH8 as a candidate gene for psychomotor delay.

Authors:  Laurent Castéra; Catherine Dehainault; Dorothée Michaux; Livia Lumbroso-Le Rouic; Isabelle Aerts; Francois Doz; Anna Pelet; Jérôme Couturier; Dominique Stoppa-Lyonnet; Marion Gauthier-Villars; Claude Houdayer
Journal:  Eur J Hum Genet       Date:  2012-08-22       Impact factor: 4.246

10.  Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age.

Authors:  Victoria W Willard; Ibrahim Qaddoumi; Haitao Pan; Chia-Wei Hsu; Rachel C Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Kristin Goode; Kendra Parris; Sean Phipps
Journal:  J Clin Oncol       Date:  2021-04-23       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.